A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate

Journal of Immunological Methods

Volumn 362, Issue 1-2, 2010, Pages 180-184

  Chen, M ^a   Chang, J S ^b   Nason, M ^a   Rangel, D ^c   Gall, J G ^c   Graham, B S ^a   Ledgerwood, J E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c GENVEC INC   (United States)

Author keywords

Neutralizing antibody; Reporter virus; RSV

Indexed keywords

NEUTRALIZING ANTIBODY;

ACCURACY; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; REPRODUCIBILITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SENSITIVITY ANALYSIS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; FLOW CYTOMETRY; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SENSITIVITY AND SPECIFICITY;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 77958456819     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.08.005     Document Type: Article

References (13)

1. Anderson L.J., Hierholzer J.C., Bingham P.G., Stone Y.O. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 1985, 22:1050.
2. Andrewes C.H., Elford W.J. Observations on anti-phage sera: I. The percentage law. Br. J. Exp. Pathol. 1933, 14:367.
3. Collins P.L., Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 2008, 82:2040.
4. Glezen W.P., Paredes A., Allison J.E., Taber L.H., Frank A.L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 1981, 98:708.
5. Graham B.S., Perkins M.D., Wright P.F., Karzon D.T. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 1988, 26:153.
6. Hallak L.K., Collins P.L., Knudson W., Peeples M.E. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 2000, 271:264.
7. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., Young J.F. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997, 176:1215.
8. Klasse P.J., Sattentau Q.J. Mechanisms of virus neutralization by antibody. Curr. Top. Microbiol. Immunol. 2001, 260:87.
9. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., Andrews C.A., Xu Q., Davis B.S., Nason M., Fay M., Koup R.A., Roederer M., Bailer R.T., Gomez P.L., Mascola J.R., Chang G.J., Nabel G.J., Graham B.S. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 2007, 196:1732.
10. Martin J.E., Louder M.K., Holman L.A., Gordon I.J., Enama M.E., Larkin B.D., Andrews C.A., Vogel L., Koup R.A., Roederer M., Bailer R.T., Gomez P.L., Nason M., Mascola J.R., Nabel G.J., Graham B.S. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 2008, 26:6338.
11. Mascola J.R., Louder M.K., Winter C., Prabhakara R., De Rosa S.C., Douek D.C., Hill B.J., Gabuzda D., Roederer M. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 2002, 76:4810.
12. Pierson T.C., Sanchez M.D., Puffer B.A., Ahmed A.A., Geiss B.J., Valentine L.E., Altamura L.A., Diamond M.S., Doms R.W. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 2006, 346:53.
13. Sashihara J., Burbelo P.D., Savoldo B., Pierson T.C., Cohen J.I. Human antibody titers to Epstein-Barr virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology 2009, 391:249.